

PATENT COOPERATION TREATY

UEXKÜLL & STOLBERG

BEST AVAILABLE COPY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

27. März 2006

PCT

To:

GROSS, Ulrich-Maria
Uexküll & Stolberg
Beselerstrasse 4
22607 Hamburg
ALLEMAGNE

T: UMa

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
REPORT ON PATENTABILITY

(PCT Rule 71.1)

Date of mailing
(day/month/year)

27.03.2006

Applicant's or agent's file reference
P66981

IMPORTANT NOTIFICATION

International application No.
PCT/EP2004/014102

International filing date (day/month/year)
10.12.2004

Priority date (day/month/year)
16.12.2003

Applicant
KRKA, TOVARNA ZDRAVIL, D.D. NOVO MEST et al

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international
preliminary examining authority:



European Patent Office - P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk - Pays Bas
Tel. +31 70 340 - 2040 Tx: 31 651 epo nl
Fax: +31 70 340 - 3016

Authorized Officer

Janzing, M

Tel. +31 70 340-4140





PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P66981		FOR FURTHER ACTION		See Form PCT/PEA/416
International application No. PCT/EP2004/014102		International filing date (day/month/year) 10.12.2004		Priority date (day/month/year) 16.12.2003
International Patent Classification (IPC) or national classification and IPC INV. C07C213/08 C07C217/74				
Applicant KRKA, TOVARNA ZDRAVIL, D.D. NOVO MEST et al				
<p>1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 5 sheets, including this cover sheet.</p> <p>3. This report is also accompanied by ANNEXES, comprising:</p> <p>a. <input checked="" type="checkbox"/> sent to the applicant and to the International Bureau) a total of 2 sheets, as follows:</p> <p><input checked="" type="checkbox"/> sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).</p> <p><input type="checkbox"/> sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.</p> <p>b. <input type="checkbox"/> (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).</p>				
<p>4. This report contains indications relating to the following items:</p> <p><input checked="" type="checkbox"/> Box No. I Basis of the report</p> <p><input type="checkbox"/> Box No. II Priority</p> <p><input type="checkbox"/> Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p><input type="checkbox"/> Box No. IV Lack of unity of invention</p> <p><input checked="" type="checkbox"/> Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p><input type="checkbox"/> Box No. VI Certain documents cited</p> <p><input type="checkbox"/> Box No. VII Certain defects in the international application</p> <p><input type="checkbox"/> Box No. VIII Certain observations on the international application</p>				
Date of submission of the demand 14.07.2005		Date of completion of this report 27.03.2006		
Name and mailing address of the international preliminary examining authority:  European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016		Authorized officer Zervas, B Telephone No. +31 70 340-3667 		

INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITYInternational application No.
PCT/EP2004/014102**Box No. I Basis of the report**

1. With regard to the **language**, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ This report is based on translations from the original language into the following language, which is the language of a translation furnished for the purposes of:
- ☐ international search (under Rules 12.3 and 23.1(b))
 - ☐ publication of the international application (under Rule 12.4)
 - ☐ international preliminary examination (under Rules 55.2 and/or 55.3)
2. With regard to the **elements*** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:

Description, Pages

1-8 received on 20.12.2005 with letter of 16.12.2005

Claims, Numbers

1-26 as originally filed

☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing

3. ☒ The amendments have resulted in the cancellation of:

- ☐ the description, pages
- ☒ the claims, Nos. 9-26
- ☐ the drawings, sheets/figs
- ☐ the sequence listing (*specify*):
- ☐ any table(s) related to sequence listing (*specify*):

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/figs
- ☐ the sequence listing (*specify*):
- ☐ any table(s) related to sequence listing (*specify*):

* If item 4 applies, some or all of these sheets may be marked "superseded."

**INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY**

International application No.
PCT/EP2004/014102

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	1-8
	No: Claims	
Inventive step (IS)	Yes: Claims	
	No: Claims	1-8
Industrial applicability (IA)	Yes: Claims	1-8
	No: Claims	

2. Citations and explanations (Rule 70.7):

see separate sheet

**INTERNATIONAL PRELIMINARY
REPORT ON PATENTABILITY
(SEPARATE SHEET)**

International application No.

PCT/EP2004/014102

Re Item V**Reasoned statement with regard to novelty, inventive step or industrial applicability;
citations and explanations supporting such statement**

Reference is made to the following document:

D1: WO 02/45658 A (TEVA PHARMACEUTICAL INDUSTRIES LTD; TEVA
PHARMACEUTICALS USA, INC; DOL) 13 June 2002 (2002-06-13)**1. Novelty**

The present application does meet the criteria of Article 33(1) PCT, because the subject-matter of claims 1 - 8 is new in the sense of Article 33(2) PCT.

The subject-matter of claim 1 and dependent claims 2 - 8 is novel, because the prior art does not disclose a process for preparing venlafaxine which comprises the conversion of a venlafaxine precursor in the presence of a salt of formic acid wherein the molar ratio of the salt of formic acid to the venlafaxine precursor is 0.3-10 to 1.

2. Inventive Step

The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claims 1 - 8 does not involve an inventive step in the sense of Article 33(3) PCT.

The document D1 is regarded as representing the closest prior art. D1 discloses the preparation of venlafaxine from a venlafaxine precursor in the presence of a salt of formic acid wherein the molar ratio of the salt of formic acid to the venlafaxine precursor is 0.1 to 1. In view of D1 the problem underlying the present application is defined as providing an alternative process for the preparation of venlafaxine. To solve this problem the Applicant provides the process of the present application which differs from the prior art process in that the amount of formic acid salt in relation to the venlafaxine precursor is higher. However, such a modification of the reaction parameters is regarded as common practice for the person skilled in the art and does consequently not involve an inventive step. An inventive step could only be acknowledged if the Applicant could verify unexpected effects resulting from such a modification of a parameter e.g. by means of a

convincing comparative test, thus a comparative test in which the only difference between the examples and the comparative example is the modified parameter. However, no such convincing results are given in the present application.

3. Industrial Applicability

The process of the present application is industrial applicable. It can be used to prepare the drug venlafaxine.


4. Remark

The description should have been adapted to the amended set of claims.


CLAIMS

1. Process for preparing venlafaxine which comprises

- (a) converting a venlafaxine precursors selected from the group of *N,N*-didesmethyl venlafaxine of formula (I), a salt thereof, spiro venlafaxine of formula (II) and a salt thereof



(I)



(II)

to venlafaxine, wherein the conversion is carried out in the presence of a salt of formic acid which is selected from the group of a metal salt or an ammonium salt of formic acid, and $[-]$, and

- (b) optionally reacting the venlafaxine with an acid to prepare an acid addition salt of venlafaxine.

~~2. Process according to claim 1, [wherein the molar ratio of the salt of formic acid to the venlafaxine precursor is~~

0.3-10 to 1_x

2. Process according to claim ¹/₁, wherein the molar ratio is 0.5-3 to 1.

5 3. Process according to ~~any one of~~ claim ^{or 2}/_{1 to 3}, wherein the metal salt of formic acid is an alkali or earth alkaline metal salt of formic acid.

10 4. Process according to claim ³/₁, wherein the alkali metal salt of formic acid is a Na, K or Li salt.

15 5. Process according to any one of claims 1 to ⁴/₃, wherein in step (a) *N,N*-didesmethyl venlafaxine (I) or a salt thereof is converted to venlafaxine in the presence of formaldehyde and formic acid.

20 6. Process according to claim ⁵/₁, wherein in step (a) the *N,N*-didesmethyl venlafaxine (I) is used in form of its HCl addition salt.

25 7. Process according to claim ⁵/₁ or ⁶/₁, wherein in step (a) the conversion is effected in the presence of also an alkali metal or earth alkaline metal hydroxide or NH_4OH in such an amount that it forms in-situ the salt of formic acid.

30 8. Process according to claim ⁷/₁, wherein the alkali metal hydroxide is NaOH which forms in-situ Na formiate.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.